Sensitivity to bleomycin-induced lung injury is not moderated by an antigen-limited T-cell repertoire

Experimental Lung Research

Volumn 31, Issue 7, 2005, Pages 685-700

  Thatcher, Thomas H ^a,b   Sime, Patricia J ^a   Barth, Richard K ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

Alpha smooth muscle actin; Bleomycin; Fibrosis; Myofibroblasts; T cells; T cell repertoire

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AUTOANTIGEN; BLEOMYCIN; CYTOCHROME C; CYTOKINE; LACTATE DEHYDROGENASE; LYSOZYME; MYOGLOBIN; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROGENESIS; HISTOPATHOLOGY; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG INJURY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; BLEOMYCIN; CHICKENS; GENES, T-CELL RECEPTOR BETA; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MURAMIDASE; PULMONARY FIBROSIS; T-LYMPHOCYTES;

EID: 25444522187     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140591007218     Document Type: Article

References (64)

1. Goldstein RH, Fine A: Fibrotic reactions in the lung: the activation of the lung fibroblast. Exp Lung Res. 1986;11:245-261.
2. Reiser KM, Last JA: Early cellular events in pulmonary fibrosis. Exp Lung Res. 1986;10:331-355.
3. Olman MA, Simmons WL, Pollman DJ, Loftis AY, Bini A, Miller EJ, Fuller GM, Rivera KE: Polymerization of fibrinogen in murine bleomycin-induced lung injury. Am J Physiol. 1996;271: L519-L526.
4. Abid SH, Malhotra V, Perry MC: Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol. 2001;13:242-248.
5. Lossos IS, Breuer R, Shriki M, Or R: Peribronchial lymphocyte activation in bleomycin-induced lung injury. Life Sciences. 1998;63:1183-1193.
6. Hunninghake GW, Kawanami O, Ferrans VJ, Young RC Jr, Roberts WC, Crystal RG: Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with inter-stitial lung disease. Am Rev Respir Dis. 1981;123:407-412.
7. Thrall RS, Barton RW, D'Amato DA, Sulavik SB: Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis. 1982;126:488-492.
8. Thrall RS, Barton RW: A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1984;129:279-832.
9. Janick-Buckner D, Ranges GE, Hacker MP: Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol Appl Pharmacol. 1989;100:465-473.
10. Sime PJ, O'Reilly KM: Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99:308-319.
11. Kunkel SL, Chensue SW, Lukacs N, Hogaboam C: Cytokine phenotypes serve as a paradigms for experimental immune-mediated lung diseases and remodeling. Am J Respir Cell Mol Biol. 2003;29:S63-S66.
12. Marshall BG, Shaw RJ: T cells and fibrosis. Chem Immunol. 2000;78:148-158.
13. Kelly M, Kolb M, Bonniaud P, Gauldie J: Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des. 2003;9:39-49.
14. Bartram U, Speer CP: The role of transforming growth factor beta in lung development and disease. Chest. 2004;125:754-765.
15. Zhang-Hoover J, Sutton A, van Rooijen N, Stein-Streilein J: A critical role for alveolar macrophages in elicitation of pulmonary immune fibrosis. Immunology. 2000;101:501-511.
16. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996;271:17779-17784.
17. Phan SH, Kunkel SL: Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992;18:29-43.
18. Silvera MR, Sempowski GD, Phipps RP: Expression of TGF-beta isoforms by Thy-1 + and Thy-1 -pulmonary fibroblast subsets: evidence for TGF-beta as a regulator of IL-1-dependent stimulation of IL-6. Lymphokine Cytokine Res. 1994;13:277-285.
19. Fries KM, Felch ME, Phipps RP: Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am J Respir Cell Mol Biol. 1994;11:552-560.
20. Cooper JA Jr: Pulmonary fibrosis: pathways are slowly coming into light. Am J Respir Cell Mol Biol. 2000;22:520-523.
21. Sharma SK, MacLean JA, Pinto C, Kradin RL: The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med. 1996;154:193-200.
22. Lossos IS, Or R, Goldstein RH, Conner MW, Breuer R: Amelioration of bleomycin-induced pulmonary injury by cyclosporin A. Exp Lung Res. 1996;22:337-349.
23. Sendelbach LE, Lindenschmidt RC, Witschi HP: The effect of cyclosporin A on pulmonary fibrosis induced by butylated hydroxytoluene, bleomycin and beryllium sulfate. Toxicol Lett. 1985;26: 169-173.
24. Selman M, Gonzalez G, Bravo M, Sullivan-Lopez J, Ramos C, Montano M, Barquin N, Vadillo F: Effect of lung T lymphocytes on fibroblasts in idiopathic pulmonary fibrosis and extrinsic allergic alveolitis. Thorax. 1990;45:451-455.
25. Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM: T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol. 1999;65:187-195.
26. Corsini E, Luster MI, Mahler J, Craig WA, Blazka ME, Rosenthal GJ: A protective role for T lymphocytes in asbestos-induced pulmonary inflammation and collagen deposition. Am J Respir Cell Mol Biol. 1994;11:531-539.
27. Pfau JC, Brown JM, Holian A: Silica-exposed mice generate autoantibodies to apoptotic cells. Toxicology. 2004;195:167-176.
28. Nakama K, Miyazaki Y, Nasu M: Immunophenotyping of lymphocytes in the lung interstitium and expression of osteopontin and interleukin-2 mRNAs in two different murine models of pulmonary fibrosis. Exp Lung Res. 1998;24:57-70.
29. Burns RP, Natarajan K, Locascio NJH, O'Brien DP, Kobori JA, Shastri N, Barth RK: Molecular analysis of skewed Tcra-V gene use in T-cell receptor β-chain transgenic mice. Immunogenetics. 1998;47:107-114.
30. O'Brien DP, Baecher-Allan CM, Burns RP, Shastri N, Barth RK: Elimination of T-cell receptor beta-chain diversity in transgenic mice restricts antigen-specific but not alloreactive responses. Immunology. 1997;91:375-382.
31. Schrier DJ, Kunkel RG, Phan SH: The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Resp Dis. 1983;127:63-66.
32. Shastri N, Gammon G, Miller A, Sercarz EE: SIa molecule-associated selectivity in T cell recognition of a 23-amino-acid peptide of lysozyme. J Exp Med. 1986;164:882.
33. Thatcher TH, O'Brien DP, Altuwaijri S, Barth RK: Increasing the frequency of T-cell precursors specific for a cryptic epitope of hen-egg lysozyme converts it to an immunodominant epitope. Immunology. 2000;99:235-242.
34. Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M, Gauldie J: Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am Respir Crit Care Med. 2001;163:770-777.
35. Baecher-Allan CM, Barth RK: PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Region Immunol. 1993;5:207-217.
36. Gammon G, Geysen HM, Apple RJ, Pickett E, Palmer M, Ametani A, Sercarz EE: T cell determinant structure: ores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med. 1991;173:609-617.
37. Solinger AM, Ultee ME, Margoliash E, Schwartz RH: T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J Exp Med. 1979;150:830-848.
38. Klein J: Biology of the Mouse Histocompatibility-2 Locus. New York: Springer-Verlag; 1975.
39. Gammon G, Shastri N, Cogswell J, Wilbur S, Sadegh-Nasseri S, Krzych U, Miller A, Sercarz E: The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev. 1987;98:53-73.
40. White ES, Lazar MH, Thannickal VJ: Pathogenetic mechanisms in usual interstitial pneumonia/ idiopathic pulmonary fibrosis. J Pathol. 2003;201:343-354.
41. Phan SH: The myofibroblast in pulmonary fibrosis. Chest. 2002;122:286S-289S.
42. Vaughan MB, Howard EW, Tomasek JJ: Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res. 2000;257:180-189.
43. Thannickal VJ, Toews GB, White ES, Lynch JP 3rd, Martinez FJ: Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395-417.
44. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J: Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol. 1998;153:825-832.
45. Gauldie J, Sime PJ, Xing Z, Marr B, Tremblay GM: Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr Top Pathol. 1999;93: 35-45.
46. Liu JY, Sime PJ, Wu T, Warshamana GS, Pociask D, Tsai SY, Brody AR: Transforming growth factor-beta(1) overexpression in tumor necrosis factor-alpha receptor knockout mice induces fibroproliferative lung disease. Am J Respir Cell Mol Biol. 2001;25:3-7.
47. Suzuki N, Ohta K, Horiuchi T, Takizawa H, Ueda T, Kuwabara M, Shiga J, Ito K: T lymphocytes and silica-induced pulmonary inflammation and fibrosis in mice. Thorax. 1996;51:1036-1042.
48. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170:655-663.
49. Schrier DJ, Phan SH, McGarry BM: The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Resp Dis. 1983;127:614-617.
50. Kremer S, Breuer R, Lossos IS, Berkman N, Christensen TG, Connor MW, Goldstein RH, Or R: Effect of immunomodulators on bleomycin-induced lung injury. Respiration. 1999;66:455-462.
51. Ohtani Y, Saiki S, Sumi Y, Inase N, Miyake S, Costabel U, Yoshizawa Y: Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol. 2003;90:604-610.
52. Luft FC: When connective tissues lay it on a bit too thick: systemic sclerosis, autoantibodies, and fibrous tissue proliferation. J Mol Med. 1998;76:1-2.
53. Keane MP, Strieter RM: The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res. 2002;3:5.
54. Keane MP, Belperio JA, Burdick MD, Strieter RM: IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2001;281:L92-L97.
55. Kalra S, Utz JP, Ryu JH: Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc. 2003;78:1082-1087.
56. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264-1269.
57. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125-133.
58. Belperio JA, Dy M, Murray L, Burdick MD, Xue W, Strieter RM, Keane MP: The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol. 2004;173:4692-4698.
59. Maeyama T, Kuwano K, Kawasaki M, Kunitake R, Hagimoto N, Hara N: Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12. Am J Physiol Lung Cell Mol Physiol. 2001;280:L1128-L1137.
60. Okazaki T, Nakao A, Nakano H, Takahashi F, Takahashi K, Shimozato O, Takeda K, Yagita H, Okumura K: Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J Immunol. 2001;167:1977-1981.
61. Janick-Buckner D, Ranges GE, Hacker MP: Effect of cytotoxic monoclonal antibody depletion of T-lymphocyte subpopulations on bleomycin-induced lung damage in C57BL/6J mice. Toxicol Appl Pharmacol. 1989;100:474-484.
62. Du M, Irani RA, Stivers DN, Lee SJ, Travis EL: H2-ea deficiency is a risk factor for bleomycin-induced lung fibrosis in mice. Cancer Res. 2004;64:6835-6839.
63. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M: Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res. 1998;24:721-743.
64. Kimura T, Ishii Y, Morishima Y, Shibuya A, Shibuya K, Taniguchi M, Mochizuki M, Hegab AE, Sakamoto T, Nomura A, Sekizawa K: Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J Immunol. 2004;172:5782-5789.